Published in Cancer Weekly, April 2nd, 2002
This combination treatment demonstrated a one-year survival rate of 27%, which is greater than that reported with gemcitabine alone in previous studies of patients with advanced pancreatic cancer (15% and 18% 1-year survival rates, respectively). This new study finding has been published in the March 2002 issue of the Journal of Clinical Oncology.
"The findings suggest that the addition of irinotecan to gemcitabine may enhance the clinical benefit of gemcitabine as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.